Today on MedNet21, we're going to discuss Lymphadenopathy and New Treatments for Lymphoproliferative Disorders.
Overview of strategies for approaching a patient with undifferentiated lymph node enlargement
including differential diagnosis considerations and considerations related to evaluation and management.
Also, we briefly review novel immune-based treatments in patients with B-cell non-Hodgkin lymphoma. We will discuss treatment with Chimeric Antigen Receptor (CAR) T cells, which is currently approved in several types of B-cell non-Hodgkin lymphoma, as well as the Bispecific T cell engagers (BiTEs).
Dates and Times
End Date: 4/16/2024
ObjectivesAs a result of this educational activity, webcast participants will be able to: review the mechanisms
of action and clinical data of (CAR) T cells and BiTEs in patients with relapsed/refractory B-cell non-Hodgkin lymphoma; highlight unique toxicities associated with CAR T cells and BiTEs: cytokines release syndrome and neurotoxicity; recognize the leading differential diagnosis considerations for
a patient presenting with undifferentiated lymphadenopathy; and Differentiate diagnostic biopsy approaches including fine needle aspiration, core needle biopsy, and excisional lymph node biopsy.
The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians
The Center for Continuing Medical Education (CCME) at The Ohio State University designates this webcasts for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.